BioCentury
ARTICLE | Company News

Seattle Genetics, GlaxoSmithKline deal

January 4, 2010 8:00 AM UTC

GlaxoSmithKline received exclusive, worldwide rights to use Seattle Genetics' antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK. Seattle Genetics will receive $12 mill...